IP Library › Granted Patent US 7,151,135
Granted Patent B2
US 7,151,135 · App. 11/078,254 · Granted Dec 19, 2006

Crosslinked polymer compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,151,135
App. No.
11/078,254
Granted
Dec 19, 2006
Kind
B2
Abstract

Provided are crosslinked polymer compositions that include a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol that has been modified to contain multiple nucleophilic groups, such as primary amino (—NH 2 ) or thiol (—SH) groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer, which contains or has been derivatized to contain, two or more electrophilic groups, such as succinimidyl groups. The compositions may further include other components, such as naturally occurring polysaccharides or proteins (such as glycosaminoglycans or collagen) and/or biologically active agents. Also disclosed are methods for using the crosslinked polymer compositions to effect adhesion between a first surface and a second surface; to effect tissue augmentation; to prevent the formation of surgical adhesions; and to coat a surface of a synthetic implant.

Claims (78)

1. A crosslinkable composition comprised of:

(a) a first crosslinkable component having m nucleophilic groups, wherein m≧2; and

(b) a second crosslinkable component having n electrophilic groups capable of reaction with the m nucleophilic groups to form covalent bonds,

wherein n≧2 and m+n≧5, the first component comprises two or more amino acid residues selected from the group consisting of amino acids comprising primary amine groups and amino acids comprising thiol groups, the second component comprises a polyethylene glycol moiety, and each of the first and second crosslinkable components is biocompatible, synthetic, and nonimmunogenic.

2. The composition of claim 1 , wherein m>3.

3. The composition of claim 1 , wherein m=3.

4. The composition of claim 1 , wherein m=4.

5. The composition of claim 1 , wherein n=4.

6. The composition of claim 1 , wherein the electrophilic groups are succinimidyl moieties.

7. The composition of claim 1 , wherein all n are identical, and all m are identical.

8. The composition of claim 1 , wherein the amino acid residues are lysine.

9. The composition of claim 8 , wherein m>3.

10. The composition of claim 8 , wherein m=3.

11. The composition of claim 8 , wherein m=4.

12. The composition of claim 8 , wherein n=4.

13. The composition of claim 8 , wherein the electrophilic groups are succinimidyl moieties.

14. The composition of claim 8 , wherein all n are identical, and all m are identical.

15. The composition of claim 1 , wherein the amino acid residues are cysteine.

16. The composition of claim 15 , wherein m>3.

17. The composition of claim 15 , wherein m=3.

18. The composition of claim 15 , wherein m=4.

19. The composition of claim 15 , wherein n=4.

20. The composition of claim 15 , wherein the electrophilic groups are succinimidyl moieties.

21. The composition of claim 15 , wherein all n are identical, and all m are identical.

22. A crosslinkable composition comprised of:

(a) a first crosslinkable component having m nucleophilic groups, wherein m≧2; and

(b) a second crosslinkable component having n electrophilic groups capable of reaction with the m nucleophilic groups to form covalent bonds,

wherein n≧2 and m+n≧5, the first component comprises two or more amino acid residues selected from the group consisting of amino acids comprising primary amine groups and amino acids comprising thiol groups, the second component comprises a polyethylene glycol moiety, the electrophilic groups are succinimidyl moieties, and each of the first and second crosslinkable components is biocompatible, synthetic, and nonimmunogenic.

23. The composition of claim 22 , wherein m>3.

24. The composition of claim 22 , wherein m=3.

25. The composition of claim 22 , wherein m=4.

26. The composition of claim 22 , wherein n=4.

27. The composition of claim 22 , wherein the electrophilic groups are succinimidyl moieties.

28. The composition of claim 22 , wherein all n are identical, and all m are identical.

29. The composition of claim 22 , wherein the selected amino acid residues are lysine.

30. The composition of claim 29 , wherein m>3.

31. The composition of claim 29 , wherein m=3.

32. The composition of claim 29 , wherein m=4.

33. The composition of claim 29 , wherein n=4.

34. The composition of claim 29 , wherein the electrophilic groups are succinimidyl moieties.

35. The composition of claim 29 , wherein all n are identical, and all m are identical.

36. The composition of claim 22 , wherein the selected amino acid residues are cysteine.

37. The composition of claim 36 , wherein m>3.

38. The composition of claim 36 , wherein m=3.

39. The composition of claim 36 , wherein m=4.

40. The composition of claim 36 , wherein n=4.

41. The composition of claim 36 , wherein the electrophilic groups are succinimidyl moieties.

42. The composition of claim 36 , wherein all n are identical, and all m are identical.

43. A crosslinkable composition comprised of:

(a) a first crosslinkable component having m nucleophilic groups, wherein m≧2; and

(b) a second crosslinkable component having n electrophilic groups capable of reaction with the m nucleophilic groups to form covalent bonds,

wherein n≧2 and m+n≧5, the first component comprises two or more amino acid residues selected from the group consisting of amino acids comprising primary amine groups and amino acids comprising thiol groups, the second component comprises a multifunctionally activated polyethylene glycol, and each of the first and second crosslinkable components is biocompatible, synthetic, and nonimmunogenic.

44. The composition of claim 43 , wherein m>3.

45. The composition of claim 43 , wherein m=3.

46. The composition of claim 43 , wherein m=4.

47. The composition of claim 43 , wherein n=4.

48. The composition of claim 43 , wherein the electrophilic groups are succinimidyl moieties.

49. The composition of claim 43 , wherein all n are identical, and all m are identical.

50. The composition of claim 43 , wherein the multifunctionally activated polyethylene glycol is tetrafunctionally activated polyethylene glycol.

51. The composition of claim 43 , wherein the multifunctionally activated polyethylene glycol is a star-branched polyethylene glycol.

52. The composition of claim 43 , wherein the amino acid residues are lysine.

53. The composition of claim 52 , wherein m>3.

54. The composition of claim 52 , wherein m=3.

55. The composition of claim 52 , wherein m=4.

56. The composition of claim 52 , wherein n=4.

57. The composition of claim 52 , wherein the electrophilic groups are succinimidyl moieties.

58. The composition of claim 52 , wherein all n are identical, and all m are identical.

59. The composition of claim 52 , wherein the multifunctionally activated polyethylene glycol is tetrafunctionally activated polyethylene glycol.

60. The composition of claim 52 , wherein the multifunctionally activated polyethylene glycol is a star-branched polyethylene glycol.

61. The composition of claim 43 , wherein the amino acid residues are cysteine.

62. The composition of claim 61 , wherein m>3.

63. The composition of claim 61 , wherein m=3.

64. The composition of claim 61 , wherein m=4.

65. The composition of claim 61 , wherein n=4.

66. The composition of claim 61 , wherein the electrophilic groups are succinimidyl moieties.

67. The composition of claim 61 , wherein all n are identical, and all m are identical.

68. The composition of claim 61 , wherein the multifunctionally activated polyethylene glycol is tetrafunctionally activated polyethylene glycol.

69. The composition of claim 61 , wherein the multifunctionally activated polyethylene glycol is a star-branched polyethylene glycol.

Assignments (13)
RELEASE OF SECURITY INTEREST : RECORDED AT REEL/FRAME - 049288/0184 Recorded Jan 29, 2021
From: CAPITAL ONE, NATIONAL ASSOCIATION
To: ANGIOTECH PHARMACEUTICALS, INC.
Reel/Frame 055171/0634 →
SECURITY INTEREST Recorded May 26, 2019
From: ANGIOTECH PHARMACEUTICALS, INC.
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 049288/0184 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2013
From: ANGIOTECH PHARMACEUTICALS (US), INC.
To: ANGIOTECH PHARMACEUTICALS, INC.
Reel/Frame 031510/0399 →
RELEASE OF SECURITY INTEREST Recorded Apr 15, 2013
From: DEUTSCHE BANK NATIONAL TRUST COMPANY
To: ANGIOTECH PHARMACEUTICALS, INC.; AMERICAN MEDICAL INSTRUMENTS HOLDINGS, INC.; ANGIOTECH AMERICA, INC.; ANGIOTECH BIOCOATINGS CORP.; ANGIOTECH PHARMACEUTICALS (US), INC.; B.G. SULZLE, INC.; MANAN MEDICAL PRODUCTS, INC.; MEDICAL DEVICE TECHNOLOGIES, INC.; QUILL MEDICAL, INC.; SURGICAL SPECIALTIES CORPORATION; ANGIOTECH INTERNATIONAL HOLDINGS CORP.
Reel/Frame 030218/0820 →
RELEASE OF SECURITY INTEREST Recorded Apr 12, 2013
From: WELLS FARGO CAPITAL FINANCE, LLC
To: ANGIOTECH PHARMACEUTICALS, INC.; AMERICAN MEDICAL INSTRUMENTS HOLDINGS, INC.; ANGIOTECH AMERICA, INC.; ANGIOTECH BIOCOATINGS CORP.; ANGIOTECH PHARMACEUTICALS (US), INC.; B.G. SULZLE, INC.; MANAN MEDICAL PRODUCTS, INC.; MEDICAL DEVICE TECHNOLOGIES, INC.; QUILL MEDICAL, INC.; SURGICAL SPECIALTIES CORPORATION; ANGIOTECH INTERNATIONAL HOLDINGS CORP.
Reel/Frame 030211/0479 →
PATENT SECURITY AGREEMENT Recorded May 13, 2011
From: ANGIOTECH PHARMACEUTICALS, INC.; AFMEDICA, INC.; AMERICAN MEDICAL INSTRUMENTS HOLDINGS, INC.; ANGIOTECH AMERICA, INC.; ANGIOTECH BIOCOATINGS CORP.; ANGIOTECH DELAWARE, INC.; ANGIOTECH FLORIDA HOLDINGS, INC.; ANGIOTECH PHARMACEUTICALS (US), INC.; B.G. SULZLE, INC.; MANAN MEDICAL PRODUCTS, INC.; MEDICAL DEVICE TECHNOLOGIES, INC.; NEUCOLL INC.; QUILL MEDICAL, INC.; SURGICAL SPECIALTIES CORPORATION; 0741693 BRITISH COLUMBIA LTD.; ANGIOTECH INTERNATIONAL HOLDINGS, CORP.
To: WELLS FARGO CAPITAL FINANCE, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 026275/0507 →
RELEASE OF SECURITY INTEREST Recorded Dec 11, 2006
From: CREDIT SUISSE
To: ANGIOTECH PHARMACEUTICALS (US), INC.
Reel/Frame 018606/0616 →
CHANGE OF NAME Recorded Aug 16, 2006
From: COHESION TECHNOLOGIES, INC.
To: ANGIOTECH BIOMATERIALS CORPORATION
Reel/Frame 018109/0551 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THE INCORPORATION OF TWO PATENT APPLICATIONS IN THE ORIGINAL ASSIGNMENT PREVIOUSLY RECORDED ON REEL 017299 FRAME 0010. ASSIGNOR(S) HEREBY CONFIRMS THE ANGIOTECH BIOMATERIALS CORP. TO ANGIOTECH PHARMACEUTICALS (US), INC. DID NOT INCLUDE THE TWO PATENT APPLICATIONS.. Recorded Aug 16, 2006
From: ANGIOTECH BIOMATERIALS CORPORATION
To: ANGIOTECH PHARMACEUTICALS (US), INC.
Reel/Frame 018114/0732 →
CORRECTIVE ASSIGNMENT TO CORRECT THE TWO PATENTS OMITTED FROM THE ORIGINAL ASSIGNMENT PREVIOUSLY RECORDED ON REEL 017299 FRAME 0949. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF THE TWO PATENT APPLICATIONS FROM ANGIOTECH BIOMATERIALS CORP. TO ANGIODEVICE INTERNATIONAL GMBH. Recorded Aug 16, 2006
From: ANGIOTECH BIOMATERIALS CORPORATION
To: ANGIODEVICE INTERNATIONAL GMBH
Reel/Frame 018114/0742 →
SECURITY AGREEMENT Recorded Apr 11, 2006
From: ANGIOTECH PHARMACEUTICALS (US), INC.
To: CREDIT SUISSE, AS COLLATERAL AGENT
Reel/Frame 017448/0600 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2006
From: ANGIOTECH BIOMATERIALS CORPORATION
To: ANGIOTECH PHARMACEUTICALS (US), INC.
Reel/Frame 017299/0010 →
CORRECTIVE CHANGE OF NAME TO REMOVE APPLICATION NUMBERS LISTED IN EXHIBIT A. DOCUMENT PREVIOUSLY RECORDED AT REEL 016369 FRAME 0932. Recorded Aug 10, 2005
From: COHESION TECHNOLOGIES, INC.
To: ANGIOTECH BIOMATERIALS CORP.
Reel/Frame 016630/0111 →